Velneperit
Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Reduced Calorie Diet
Shionogi · Phase 2 · Completed · Enrollment 724
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| S-2367 Placebo | n/r | n/r | n/r | n/r |
| S-2367 800 mg | n/r | n/r | n/r | n/r |
| S-2367 1600 mg | n/r | n/r | n/r | n/r |
Not shown
- S-2367 Placebo: endpoint not reported
- S-2367 800 mg: endpoint not reported
- S-2367 1600 mg: endpoint not reported